New England Journal of Medicine
December 17, 2020 Vol. 383 No. 25
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates E.E. Walsh and Others
The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data regarding BNT162b1 in younger adults from trials in Germany and the United States, support the selection of BNT162b2 for advancement to a pivotal phase 2–3 safety and efficacy evaluation. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728. opens in new tab.